01 Aug 2024 --- In its H1 2024 performance results, dsm-firmenich increases its outlook and forecasts an Adjusted EBITDA of around €2 billion (US$2.16 billion) in FY 2024. The ingredients giant plans to accelerate its “innovation-led” growth by prioritizing the high-growth and high-margin segments of Perfumery & Beauty. “Our relentless focus on operational excellence, combined with improving business conditions, resulted in better financial results. Perfumery & Beauty and Taste, Texture & Health both delivered a strong performance. Health, Nutrition & Care and Animal Nutrition & Health saw improved momentum,” comments CEO Dimitri de Vreeze.
